1800 Final results for overall survival (OS), the primary endpoint of the CECOG TURANDOT prospective randomised trial evaluating bevacizumab-paclitaxel (BEV-PAC) vs BEV-capecitabine (CAP) for HER2-negative locally recurrent/metastatic breast cancer (LR/mBC)
暂无分享,去创建一个
R. Greil | B. Melichar | G. Steger | M. Inbar | I. Láng | D. Sirbu | R. Anghel | T. Brodowicz | M. Dank | C. Zielinski | T. Pieńkowski | D. Messinger | A. Eniu | S. Stemmer | Z. Kahán | S. Bešlija | B. Nisenbaum | L. Petruželka | Ž. Zvirbule